{"id":781964,"date":"2023-09-06T07:20:27","date_gmt":"2023-09-06T11:20:27","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-to-highlight-clinical-value-of-idgenetix-test-at-psych-congress-2023\/"},"modified":"2023-09-06T07:20:27","modified_gmt":"2023-09-06T11:20:27","slug":"castle-biosciences-to-highlight-clinical-value-of-idgenetix-test-at-psych-congress-2023","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-to-highlight-clinical-value-of-idgenetix-test-at-psych-congress-2023\/","title":{"rendered":"Castle Biosciences to Highlight Clinical Value of IDgenetix\u00ae Test at Psych Congress 2023"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Castle Biosciences to Highlight Clinical Value of IDgenetix\u00ae Test at Psych Congress 2023<\/b><\/p>\n<p>FRIENDSWOOD, Texas&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nCastle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share a poster detailing new data regarding the Company\u2019s IDgenetix\u00ae test at the upcoming Psych Congress 2023 conference, being held in Nashville, Tennessee, Sept. 6-10. IDgenetix is Castle\u2019s advanced pharmacogenomic (PGx) test that combines a patient\u2019s drug-drug, drug-gene and lifestyle-factor interactions into a comprehensive test report designed to guide medication selection and management for patients with neuropsychiatric conditions, such as depression and anxiety.<\/p>\n<p>\nDetails regarding the poster are included below:<\/p>\n<ul class=\"bwlistdisc\">\n<li><b>Poster title:<\/b><i>The Importance of Incorporating Drug-Drug Interactions and Lifestyle Factors in Pharmacogenomics-Guided Medication Management for Patients with Major Depressive Disorder in a Randomized Controlled Trial<\/i><\/li>\n<li>\nPoster #: 83<\/p>\n<\/li>\n<li>\nDate &amp; Time: Friday, Sept. 8, and Saturday, Sept. 9, from 1:30-3 p.m. Central time each day<\/p>\n<\/li>\n<\/ul>\n<p>\nPosters will remain on display while the exhibit hall is open, Friday, Sept. 8, and Saturday, Sept. 9, from noon-3:30 p.m. Central time each day. Additionally, posters will be available for viewing in the HMP (Healthcare Made Practical) Conferences mobile app and published on HMP Global\u2019s <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.hmpgloballearningnetwork.com%2Fsite%2Fpsychbehav%3F__hstc%3D96200195.cb0b4916ad88ddba7d0a64b8e30efe4d.1692298693682.1692298693682.1692298693682.1%26__hssc%3D96200195.3.1692305160260%26__hsfp%3D2968214243&amp;esheet=53549275&amp;newsitemid=20230906511575&amp;lan=en-US&amp;anchor=Psychiatry+%26amp%3B+Behavioral+Health+Learning+Network&amp;index=1&amp;md5=02321316110a65982303c6ac5deb06c3\">Psychiatry &amp; Behavioral Health Learning Network<\/a> 30-60 days after the event ends.<\/p>\n<p><b>About IDgenetix\u00ae<\/b><\/p>\n<p>\nIDgenetix\u00ae is an advanced pharmacogenomic (PGx) test designed to guide medication selection and management for patients with neuropsychiatric conditions, such as depression and anxiety. IDgenetix provides important genetic information to clinicians to help guide personalized treatment plans for their patients, with a goal of helping patients achieve faster therapeutic response and improving their chances of remission by identifying appropriate medications more efficiently than the standard-of-care, trial-and-error approach. IDgenetix integrates drug-gene, drug-drug and lifestyle-factor interactions in a clinically actionable report and is supported by a published, peer-reviewed randomized controlled trial that demonstrated clinical utility over the standard of care when physicians reviewed IDgenetix results prior to prescribing a medication. More information can be found at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.IDgenetix.com&amp;esheet=53549275&amp;newsitemid=20230906511575&amp;lan=en-US&amp;anchor=www.IDgenetix.com&amp;index=2&amp;md5=54011f872a393601097541cfe5a15514\">www.IDgenetix.com<\/a>.<\/p>\n<p><b>About Castle Biosciences<\/b><\/p>\n<p>\nCastle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.<\/p>\n<p>\nCastle\u2019s current portfolio consists of tests for skin cancers, uveal melanoma, Barrett\u2019s esophagus and mental health conditions. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to predict systemic therapy response in patients with moderate-to-severe psoriasis, atopic dermatitis and related conditions. To learn more, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.CastleBiosciences.com&amp;esheet=53549275&amp;newsitemid=20230906511575&amp;lan=en-US&amp;anchor=www.CastleBiosciences.com&amp;index=3&amp;md5=e54505b68fd60d7ef6cf29ced63cb36f\">www.CastleBiosciences.com<\/a> and connect with us on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fcastle-biosciences-inc-%2F&amp;esheet=53549275&amp;newsitemid=20230906511575&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=4&amp;md5=12218d93251491038766435c92361cbc\">LinkedIn<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2Fcastlebiosciences%2F&amp;esheet=53549275&amp;newsitemid=20230906511575&amp;lan=en-US&amp;anchor=Facebook&amp;index=5&amp;md5=3f139822ccdec9c034c0f6f49171c962\">Facebook<\/a>, <a rel=\"nofollow\" id=\"smartlink5\" href=\"https:\/\/twitter.com\/castlebio?lang=en\">X<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fcastlebiosciences%2F&amp;esheet=53549275&amp;newsitemid=20230906511575&amp;lan=en-US&amp;anchor=Instagram&amp;index=6&amp;md5=05d6366f595f6cee7b843fee085585b0\">Instagram<\/a>.<\/p>\n<p>\nDecisionDx-Melanoma, DecisionDx-CM<i>Seq<\/i>, DecisionDx-SCC, MyPath Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UM<i>Seq<\/i>, TissueCypher and IDgenetix are trademarks of Castle Biosciences, Inc.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230906511575r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20230906511575\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20230906511575\/en\/<\/a><\/span><\/p>\n<p><b>Investor Contact:<br \/>\n<\/b><br \/>Camilla Zuckero<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:czuckero@castlebiosciences.com\">czuckero@castlebiosciences.com<\/a><\/p>\n<p><b>Media Contact:<br \/>\n<\/b><br \/>Allison Marshall<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:amarshall@castlebiosciences.com\">amarshall@castlebiosciences.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Texas Tennessee United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Mental Health Health Genetics Research Science Pharmaceutical Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230906511575\/en\/1881743\/3\/CastleLogo_square_for_press_releases.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Castle Biosciences to Highlight Clinical Value of IDgenetix\u00ae Test at Psych Congress 2023 FRIENDSWOOD, Texas&#8211;(BUSINESS WIRE)&#8211; Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share a poster detailing new data regarding the Company\u2019s IDgenetix\u00ae test at the upcoming Psych Congress 2023 conference, being held in Nashville, Tennessee, Sept. 6-10. IDgenetix is Castle\u2019s advanced pharmacogenomic (PGx) test that combines a patient\u2019s drug-drug, drug-gene and lifestyle-factor interactions into a comprehensive test report designed to guide medication selection and management for patients with neuropsychiatric conditions, such as depression and anxiety. Details regarding the poster are included below: Poster title:The Importance of Incorporating Drug-Drug Interactions and Lifestyle Factors in Pharmacogenomics-Guided Medication Management for Patients with &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-to-highlight-clinical-value-of-idgenetix-test-at-psych-congress-2023\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Castle Biosciences to Highlight Clinical Value of IDgenetix\u00ae Test at Psych Congress 2023&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-781964","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Castle Biosciences to Highlight Clinical Value of IDgenetix\u00ae Test at Psych Congress 2023 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-to-highlight-clinical-value-of-idgenetix-test-at-psych-congress-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Castle Biosciences to Highlight Clinical Value of IDgenetix\u00ae Test at Psych Congress 2023 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Castle Biosciences to Highlight Clinical Value of IDgenetix\u00ae Test at Psych Congress 2023 FRIENDSWOOD, Texas&#8211;(BUSINESS WIRE)&#8211; Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share a poster detailing new data regarding the Company\u2019s IDgenetix\u00ae test at the upcoming Psych Congress 2023 conference, being held in Nashville, Tennessee, Sept. 6-10. IDgenetix is Castle\u2019s advanced pharmacogenomic (PGx) test that combines a patient\u2019s drug-drug, drug-gene and lifestyle-factor interactions into a comprehensive test report designed to guide medication selection and management for patients with neuropsychiatric conditions, such as depression and anxiety. Details regarding the poster are included below: Poster title:The Importance of Incorporating Drug-Drug Interactions and Lifestyle Factors in Pharmacogenomics-Guided Medication Management for Patients with &hellip; Continue reading &quot;Castle Biosciences to Highlight Clinical Value of IDgenetix\u00ae Test at Psych Congress 2023&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-to-highlight-clinical-value-of-idgenetix-test-at-psych-congress-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-06T11:20:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230906511575r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/castle-biosciences-to-highlight-clinical-value-of-idgenetix-test-at-psych-congress-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/castle-biosciences-to-highlight-clinical-value-of-idgenetix-test-at-psych-congress-2023\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Castle Biosciences to Highlight Clinical Value of IDgenetix\u00ae Test at Psych Congress 2023\",\"datePublished\":\"2023-09-06T11:20:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/castle-biosciences-to-highlight-clinical-value-of-idgenetix-test-at-psych-congress-2023\\\/\"},\"wordCount\":513,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/castle-biosciences-to-highlight-clinical-value-of-idgenetix-test-at-psych-congress-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230906511575r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/castle-biosciences-to-highlight-clinical-value-of-idgenetix-test-at-psych-congress-2023\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/castle-biosciences-to-highlight-clinical-value-of-idgenetix-test-at-psych-congress-2023\\\/\",\"name\":\"Castle Biosciences to Highlight Clinical Value of IDgenetix\u00ae Test at Psych Congress 2023 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/castle-biosciences-to-highlight-clinical-value-of-idgenetix-test-at-psych-congress-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/castle-biosciences-to-highlight-clinical-value-of-idgenetix-test-at-psych-congress-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230906511575r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2023-09-06T11:20:27+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/castle-biosciences-to-highlight-clinical-value-of-idgenetix-test-at-psych-congress-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/castle-biosciences-to-highlight-clinical-value-of-idgenetix-test-at-psych-congress-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/castle-biosciences-to-highlight-clinical-value-of-idgenetix-test-at-psych-congress-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230906511575r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230906511575r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/castle-biosciences-to-highlight-clinical-value-of-idgenetix-test-at-psych-congress-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Castle Biosciences to Highlight Clinical Value of IDgenetix\u00ae Test at Psych Congress 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Castle Biosciences to Highlight Clinical Value of IDgenetix\u00ae Test at Psych Congress 2023 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-to-highlight-clinical-value-of-idgenetix-test-at-psych-congress-2023\/","og_locale":"en_US","og_type":"article","og_title":"Castle Biosciences to Highlight Clinical Value of IDgenetix\u00ae Test at Psych Congress 2023 - Market Newsdesk","og_description":"Castle Biosciences to Highlight Clinical Value of IDgenetix\u00ae Test at Psych Congress 2023 FRIENDSWOOD, Texas&#8211;(BUSINESS WIRE)&#8211; Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share a poster detailing new data regarding the Company\u2019s IDgenetix\u00ae test at the upcoming Psych Congress 2023 conference, being held in Nashville, Tennessee, Sept. 6-10. IDgenetix is Castle\u2019s advanced pharmacogenomic (PGx) test that combines a patient\u2019s drug-drug, drug-gene and lifestyle-factor interactions into a comprehensive test report designed to guide medication selection and management for patients with neuropsychiatric conditions, such as depression and anxiety. Details regarding the poster are included below: Poster title:The Importance of Incorporating Drug-Drug Interactions and Lifestyle Factors in Pharmacogenomics-Guided Medication Management for Patients with &hellip; Continue reading \"Castle Biosciences to Highlight Clinical Value of IDgenetix\u00ae Test at Psych Congress 2023\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-to-highlight-clinical-value-of-idgenetix-test-at-psych-congress-2023\/","og_site_name":"Market Newsdesk","article_published_time":"2023-09-06T11:20:27+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230906511575r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-to-highlight-clinical-value-of-idgenetix-test-at-psych-congress-2023\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-to-highlight-clinical-value-of-idgenetix-test-at-psych-congress-2023\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Castle Biosciences to Highlight Clinical Value of IDgenetix\u00ae Test at Psych Congress 2023","datePublished":"2023-09-06T11:20:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-to-highlight-clinical-value-of-idgenetix-test-at-psych-congress-2023\/"},"wordCount":513,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-to-highlight-clinical-value-of-idgenetix-test-at-psych-congress-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230906511575r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-to-highlight-clinical-value-of-idgenetix-test-at-psych-congress-2023\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-to-highlight-clinical-value-of-idgenetix-test-at-psych-congress-2023\/","name":"Castle Biosciences to Highlight Clinical Value of IDgenetix\u00ae Test at Psych Congress 2023 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-to-highlight-clinical-value-of-idgenetix-test-at-psych-congress-2023\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-to-highlight-clinical-value-of-idgenetix-test-at-psych-congress-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230906511575r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2023-09-06T11:20:27+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-to-highlight-clinical-value-of-idgenetix-test-at-psych-congress-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-to-highlight-clinical-value-of-idgenetix-test-at-psych-congress-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-to-highlight-clinical-value-of-idgenetix-test-at-psych-congress-2023\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230906511575r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230906511575r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-to-highlight-clinical-value-of-idgenetix-test-at-psych-congress-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Castle Biosciences to Highlight Clinical Value of IDgenetix\u00ae Test at Psych Congress 2023"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/781964","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=781964"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/781964\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=781964"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=781964"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=781964"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}